Joachim Eeckhout

Joachim Eeckhout

Blackstone raises record $6.3B life sciences fund & Lilly acquires Centessa for $6.3B

Blackstone raises record $6.3B life sciences fund & Lilly acquires Centessa for $6.3B

Joachim Eeckhout, +1
Kailera plans an IPO for its obesity drugs & Lilly signs a $2.75 billion AI deal Insilico Medicine

Kailera plans an IPO for its obesity drugs & Lilly signs a $2.75 billion AI deal Insilico Medicine

Joachim Eeckhout, +1
Novartis bets $2B on next-gen allergy drug & Otsuka buys an anti-PTSD drug for $700M upfront

Novartis bets $2B on next-gen allergy drug & Otsuka buys an anti-PTSD drug for $700M upfront

Joachim Eeckhout, +1
Pinnacle raises $89M for its oral peptide drugs & Beam reports positive Phase 1/2 trial of its base editing therapy

Pinnacle raises $89M for its oral peptide drugs & Beam reports positive Phase 1/2 trial of its base editing therapy

Joachim Eeckhout, +1
Merck bets $6.7B on Terns & Sarepta shows strong RNAi clinical results

Merck bets $6.7B on Terns & Sarepta shows strong RNAi clinical results

Joachim Eeckhout, +1
Gilead acquires Ouro for $1.7B & Merck pays Quotient $20 million for new IBD drugs

Gilead acquires Ouro for $1.7B & Merck pays Quotient $20 million for new IBD drugs

Joachim Eeckhout, +1
Sanofi re-enters T-cell engager space with $1.2B deal & AI biotech Earendil raises $787 million

Sanofi re-enters T-cell engager space with $1.2B deal & AI biotech Earendil raises $787 million

Joachim Eeckhout, +1
Novartis buys a next-gen breast cancer drug for up to $3 billion & Congruence raises $39.5 million

Novartis buys a next-gen breast cancer drug for up to $3 billion & Congruence raises $39.5 million

Joachim Eeckhout, +1
Pfizer’s PARP inhibitor scores clinical win & Lilly's triple-agonist diabetes drug shows positive Phase 3 results

Pfizer’s PARP inhibitor scores clinical win & Lilly's triple-agonist diabetes drug shows positive Phase 3 results

Joachim Eeckhout, +1
Two next-gen T cell engager companies raised a combined $146M & Aspen shows promising early results in Parkinson’s

Two next-gen T cell engager companies raised a combined $146M & Aspen shows promising early results in Parkinson’s

Joachim Eeckhout, +1